<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714827</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-T SXZL03</org_study_id>
    <nct_id>NCT04714827</nct_id>
  </id_info>
  <brief_title>Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Clinical Study to Evaluate the Safety and Effectiveness of CD19- BCMA CAR - T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Ultra-T Immune Therapeutics Co. LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanxi Province Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-BCMA CAR-T cells&#xD;
      for the treatment of multiple myeloma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non randomized study ,plans to enrollment 24 patients of B cell lymphoma ，divided into low,&#xD;
      medium and high dose groups，to evaluate the safety and tolerability of CD19-BCMA CAR - T&#xD;
      cells immunotherapy in patients with relapsed or refractory B cell lymphoma ，to evaluate the&#xD;
      preliminary efficacy and observe PK/PD parameters of CD19-BCMA CAR - T cells immunotherapy in&#xD;
      patients with relapsed or refractory multiple myeloma .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>Form infusion CAR-T cells to 28 days after infusion</time_frame>
    <description>Observe wether dose limiting toxicity will happened in dose escalation phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Form infusion CAR-T cells to 2 years after infusion</time_frame>
    <description>The overall response rate after CAR-T Cells immunotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of various types of adverse recation</measure>
    <time_frame>Form infusion CAR-T cells to 2 years after infusion</time_frame>
    <description>According to CTCAE 5.0, record the level , type of adverse events, evaluat the correlation of CD19-BCMA CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Form infusion CAR-T cells to 2 years after infusion</time_frame>
    <description>Progression-free surial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Form infusion CAR-T cells to 2 years after infusion</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Form infusion CAR-T cells to subjects died，assessed up to 60 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24</time_frame>
    <description>By measuring the CAR - T cells copy number and the positive rate, peak plasma concentration is determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24</time_frame>
    <description>The maximum concentration of time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC（0-720d）</measure>
    <time_frame>Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of IL2 level</measure>
    <time_frame>Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24</time_frame>
    <description>The levels of cytokines（IL2 ）in peripheral blood and bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of IL6 level</measure>
    <time_frame>Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24</time_frame>
    <description>The levels of cytokines（ IL6 ）in peripheral blood and bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of IL10 level</measure>
    <time_frame>Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24</time_frame>
    <description>The levels of cytokines（IL10 ）in peripheral blood and bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of TNF-α level</measure>
    <time_frame>Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24</time_frame>
    <description>The levels of cytokines（TNF-α ）in peripheral blood and bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of IFN-γ level</measure>
    <time_frame>Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24</time_frame>
    <description>The levels of cytokines（IFN-γ ）in peripheral blood and bone marrow</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Low Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 1.0×10^6 CAR+T cells/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2.5×10^6 CAR+T cells/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5.0×10^6 CAR+T cells/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplification Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19-BCMA CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 1.0-5.0×10^6 CAR+Tcells/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-CD22 CAR-T cells</intervention_name>
    <description>A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-BCMA CAR-T cells .</description>
    <arm_group_label>Amplification Dose Group</arm_group_label>
    <arm_group_label>High Dose Group</arm_group_label>
    <arm_group_label>Low Dose Group</arm_group_label>
    <arm_group_label>Middle Dose Group</arm_group_label>
    <other_name>Fluorine dara marina injection</other_name>
    <other_name>Cyclophosphamide injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Agreed to participate in this study and signed informed consent, and willing to finish&#xD;
             all the test procedure.&#xD;
&#xD;
          2. Age ≧ 18 years of age, gender not limited;&#xD;
&#xD;
          3. According to IMWG， diagnosis of multiple myeloma patients;&#xD;
&#xD;
          4. ECOG physical score ≤2 points ;&#xD;
&#xD;
          5. Relapsed multiple myeloma: disease progressed after received at least 3 lines&#xD;
             treatment (must including the proteasome inhibitors and immune modulators); Refractory&#xD;
             multiple myeloma: early treatment has never reached more than MR and curative effect;&#xD;
             Or early treatment has reached more than MR and curative effect, but the subsequent&#xD;
             treatment process or disease progress within 60 days after the last treatment ;&#xD;
&#xD;
          6. Have a measurable lesions in screening period (conform to one of the following&#xD;
             standards: (1) the serum M protein: IgG protein≥10g/L, or IgA M protein ≥5g/L, or IgD&#xD;
             M protein ≥5g/L; (2) M protein urine ≥200mg/24h; (3)If M protein in serum or urine&#xD;
             cannot be measured,under the condition of the abnormal serum free light chain&#xD;
             ratio,serum free light chain immunoglobulin or 100 mg/L;&#xD;
&#xD;
          7. Test results in screening period: (1) Hb≥60 g/L (7 days before the inspection without&#xD;
             blood transfusion),PLT≥ 50 x 10 ^ 9 / L(7 days before the inspection without blood&#xD;
             transfusion) ,ALC≥0.3×10^9/L,ANC≥0.75×10^9/L; (2)AST≤3ULN,ALT≤3ULN,TBIL≤2ULN；Ccr≥30&#xD;
             mL/min/1.73 m2;Correction of serum calcium ≤3.1mmol/L（≤12.5mg/dL）; LVEF≥40%； Baseline&#xD;
             peripheral blood oxygen saturation ≥95%;&#xD;
&#xD;
          8. Female subjects with fertility ,pregnancy blood test results should be negative in&#xD;
             screening period and before remove the lymphocyte ;&#xD;
&#xD;
          9. Expected to survival more than 3 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The active hepatitis b, HBV - DNA detection lower limit of the subjects above research&#xD;
             center; Hepatitis c virus (HCV) antibody positive and peripheral blood HCV - RNA&#xD;
             positive subjects; Antibodies to HIV positive subjects; Early syphilis screening&#xD;
             antibody positive;&#xD;
&#xD;
          2. The other clinical significance of active virus, bacterial infection, or failing to&#xD;
             control systemic fungal infection;&#xD;
&#xD;
          3. Any instability of systemic disease, including but not limited to, unstable angina,&#xD;
             cerebrovascular accident, or transient ischemic (within 6 months prior to screening),&#xD;
             myocardial infarction (within 6 months prior to screening), New York heart association&#xD;
             (NYHA) classification level III or higher congestive heart failure, drug control of&#xD;
             serious arrhythmia, liver, kidney or metabolic diseases, as well as the standard&#xD;
             treatment cannot control high blood pressure;&#xD;
&#xD;
          4. In past two years, because of autoimmune diseases such as crohn's disease, rheumatoid&#xD;
             arthritis and systemic lupus erythematosus (sle), etc.) causing end-organ damage, or&#xD;
             need systemic application of immunosuppressive drugs;&#xD;
&#xD;
          5. Had a history of the central nervous system diseases, such as epilepsy, serious brain&#xD;
             damage, dementia, Parkinson's disease, psychosis,etc which influence the appraising of&#xD;
             test,;&#xD;
&#xD;
          6. Diagnosed with other active malignancy in past five years(the basal or scaly skin&#xD;
             cancer, superficial bladder cancer, breast cancer in situ, which has been cured and&#xD;
             does not require follow-up treatment are not included );&#xD;
&#xD;
          7. Known allergic to cyclophosphamide, fluorine dara marina or CAR - T cell s including&#xD;
             accessories, DMSO ;&#xD;
&#xD;
          8. Patients with pregnancy or lactation, patients do not want to take effective&#xD;
             contraceptive measures within 6months after infusion CAR-T cells;&#xD;
&#xD;
          9. The other situations that researchers determined doesn't fit to participate in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liping Su, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Department of ShanXi Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liping Su, M.D.</last_name>
    <phone>13835158122</phone>
    <phone_ext>+86</phone_ext>
    <email>sulp2005@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology Department of ShanXi Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Guan, PhD</last_name>
      <phone>+8613509717461</phone>
      <email>395714554@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 17, 2021</last_update_submitted>
  <last_update_submitted_qc>January 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to Share Clinical Study Report within six months after the study completed</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Within six months after the study completed</ipd_time_frame>
    <ipd_access_criteria>Research site</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

